URINARY INTERLEUKIN-2 MONITORING DURING PROLONGED BACILLUS CALMETTE-GUERIN TREATMENT: CAN IT PREDICT THE OPTIMAL NUMBER OF INSTILLATIONS?
- 1 January 1999
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 161 (1) , 67-71
- https://doi.org/10.1016/s0022-5347(01)62065-2
Abstract
Purpose: In patients with superficial bladder cancer treated with a first B-week instillation course of bacillus Calmette-Guerin (BCG) the induction pattern of urinary interleukin (IL)-2 has been described, and the levels of urinary IL-2 were associated with the clinical response to BCG treatment. We evaluated urinary IL-2 kinetics in patients with recurrent superficial bladder tumor receiving a second or third 6-week BCG instillation course. To our knowledge there have been no studies of prolonged BCG treatment and urinary cytokine responses. Materials and Methods: Urinary IL-2 was determined in 12 patients with superficial transitional cell carcinoma of the bladder receiving a complete (6-week) second or third BCG instillation course and in 3 patients receiving 3 BCG instillations during a maintenance schedule at month 3. Urinary IL-2 was determined with an enzyme-linked immunosorbent assay using an oligoclonal system. Results: Of 12 patients 10 had a urinary IL-2 positive response during the subsequent BCG course and at week 1 urinary IL-2 was already increased. Comparing the urinary IL-2 kinetics observed during a second or third with a first course, urinary IL-2 tended to be higher during the first and lower during the last weeks. If the interval between subsequent courses was short (12 months or less) significantly higher urinary IL-2 levels at weeks 1 and 2, and a fewer level at week 6 were observed. Conclusions: During a repeat BCG instillation course urinary IL-2 reached a maximum at an earlier week, especially if the interval between the subsequent courses was short. Since an association between urinary IL-2 levels and response to BCG treatment during an induction course has been observed, these immunological data argue in favor of a Limited number of instillations during prolonged BCG therapy which could reduce side effects as well as costKeywords
This publication has 28 references indexed in Scilit:
- A Randomized Prospective Study Comparing Long-Term Intravesical Instillations of Mitomycin C and Bacillus Calmette-Guerin in Patients with Superficial Bladder CarcinomaJournal of Urology, 1996
- Urinary Cytokines During Intravesical Bacillus Calmetteguerin Therapy for Superficial Bladder Cancer: Processing, Stability and Prognostic ValueJournal of Urology, 1996
- Intravesical Bacillus Calmette-Guérin versus Epirubicin in the Prophylaxis of Recurrent and/or Multiple Superficial Bladder TumoursOncology, 1996
- Factors affecting recurrence and progression in superficial bladder tumoursEuropean Journal Of Cancer, 1995
- Original Articles: Bladder Cancer: A Randomized Study of Intravesical Mitomycin C, Bacillus Calmette-Guerin Tice and Bacillus Calmette-Guerin RIVM Treatment in pTa-pT1 Papillary Carcinoma and Carcinoma in Situ of the BladderJournal of Urology, 1995
- The Th1–Th2 hypothesis of HIV infection: new insightsImmunology Today, 1994
- Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancerCancer Immunology, Immunotherapy, 1992
- Defining Protective Responses to Pathogens: Cytokine Profiles in Leprosy LesionsScience, 1991
- Lymphokine-mediated regulation of the proliferative response of clones of T helper 1 and T helper 2 cells.The Journal of Experimental Medicine, 1988
- Local Immune Responses after Intravesical BCG Treatment for Carcinoma in situBritish Journal of Urology, 1987